SV Health Investors’s Ocular Therapeutix OCUL Stock Holding History

SV Health Investors’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-312,068	Closed	-$2.6M	–	11
2020 Q2	$2.6M	Sell	312,068 -316,168	-50%	-$2.1M	1.8%	8
2020 Q1	$3.11M	Hold	628,236	–	–	2.61%	8
2019 Q4	$2.48M	Hold	628,236	–	–	1.5%	8
2019 Q3	$1.91M	Hold	628,236	–	–	1.34%	9
2019 Q2	$2.76M	Hold	628,236	–	–	1.86%	8
2019 Q1	$2.49M	Hold	628,236	–	–	1.46%	7
2018 Q4	$2.5M	Sell	628,236 -94,700	-13%	-$522K	1.54%	7
2018 Q3	$4.97M	Sell	722,936 -522,334	-42%	-$3.28M	1.46%	6
2018 Q2	$8.41M	Sell	1,245,270 -359,937	-22%	-$2.47M	3.86%	5
2018 Q1	$10.4M	Hold	1,605,207	–	–	7.84%	5
2017 Q4	$7.14M	Hold	1,605,207	–	–	3.77%	6
2017 Q3	$9.92M	Hold	1,605,207	–	–	7.52%	5
2017 Q2	$14.9M	Hold	1,605,207	–	–	16.02%	3
2017 Q1	$14.9M	Hold	1,605,207	–	–	16.45%	3
2016 Q4	$13.4M	Sell	1,605,207 -327,400	-17%	-$2.54M	11.31%	3
2016 Q3	$13.3M	Hold	1,932,607	–	–	10.2%	3
2016 Q2	$9.57M	Hold	1,932,607	–	–	9.66%	3
2016 Q1	$18.7M	Hold	1,932,607	–	–	13.95%	3
2015 Q4	$18.1M	Hold	1,932,607	–	–	14.56%	4
2015 Q3	$27.2M	Hold	1,932,607	–	–	15.2%	3
2015 Q2	$40.6M	Sell	1,932,607 -653,000	-25%	-$16.2M	15.56%	3
2015 Q1	$109M	Hold	2,585,607	–	–	35.87%	1
2014 Q4	$60.8M	Hold	2,585,607	–	–	30.35%	2
2014 Q3	$38.7M	Buy	+2,585,607	New	+$38.2M	19.31%	2

Other funds holding OCUL

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SV Health Investors's OCUL Position: Q3 2020 in Review

SV Health Investors sold out of Ocular Therapeutix (OCUL) in Q3 2020, closing a stake of 312,068 shares — an estimated $2.6M sold.

SV Health Investors first reported a position in OCUL in Q3 2014 and held it in 24 quarters. The position peaked at $109M in Q1 2015. 108 funds tracked by Wall St. Rank hold OCUL as of Q3 2020.

SV Health Investors reported no remaining Ocular Therapeutix position as of Q3 2020 after selling out during the quarter.
SV Health Investors sold 312,068 Ocular Therapeutix shares in Q3 2020, an estimated $2.6M.
SV Health Investors first reported a position in Ocular Therapeutix in Q3 2014 and held it in 24 quarters.
SV Health Investors's Ocular Therapeutix position peaked at $109M in Q1 2015.
108 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2020.

Based on SV Health Investors's 13F filing for Q3 2020, filed 12 Nov 2020.